<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254085</url>
  </required_header>
  <id_info>
    <org_study_id>2612-2368</org_study_id>
    <secondary_id>KA 03092s</secondary_id>
    <nct_id>NCT00254085</nct_id>
  </id_info>
  <brief_title>Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.</brief_title>
  <official_title>Multiple Substitution of First Phase Insulin Response With a Rapid Action Insuli Analogue in Patient With Newly Diagnosed Type 2 Diabtes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <brief_summary>
    <textblock>
      The purpose of the project is to shown whether a little dose of a short acting insulin
      analogue given 3 time daily before the meals compared with placebo could normalise the
      increase in blood glucose after teh meals in diet treated Type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Type 2 diabtes has a defect in the insulinsecretion combined with an increased
      insulin resistance. At an intravenously glucosestimulation, patients with Type 2 diabtes has
      a decresed first phase insulin response compared to healty peoples. Because the hyperglycemia
      after meal, observed i Type 2 diabetics patients, is related to the defect in the first phase
      insulin response it is our hypothesis that substitution of the first phase insulin response
      with a little dose of insulin could normalise the blood glucose after the meal.

      20 patients with Type 2 diabetes will in a randomised, placebocontrolled, dobble-dummy study
      be included for three days treatment with Insulin aspart vs placebo. Primary endpoint is
      bloodglucose fluctuations monitored by a continously glucose monitor.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose fluctuations</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of hypoglycemia</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabtes according to the WHO criteria Fasting blood glucose &gt;7 HbA1c between 6-9
        Normal liver function Normal renal function

        Exclusion Criteria:

        Ongoing treatment with antidiabetic medicine Pregnancy and lactation -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Gredal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Gredal, MD</last_name>
    <phone>+45 39 77 79 76</phone>
    <email>chgr@gentoftehosp.kbhamt.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gentofte University Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Gredal, MD</last_name>
      <phone>+45 39 77 79 76</phone>
      <email>chgr@gentoftehosp.kbhamt.dk</email>
    </contact>
    <investigator>
      <last_name>Charlotte Gredal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>November 14, 2005</last_update_submitted>
  <last_update_submitted_qc>November 14, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2005</last_update_posted>
  <keyword>Type 2 diabtes</keyword>
  <keyword>Postprandial hyperglycemia</keyword>
  <keyword>Insulin treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

